VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

N. caninum NcPDI Protein Vaccine
Vaccine Information
  • Vaccine Name: N. caninum NcPDI Protein Vaccine
  • Target Pathogen: Neospora caninum
  • Target Disease: Neosporosis
  • Vaccine Ontology ID: VO_0004009
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Recombinant NcPDI protein (Debache et al., 2010).
  • PDI gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Adjuvant:
    • Adjuvant name:
    • VO adjuvant ID: VO_0000143
    • Description: Cholera toxin adjuvant (Debache et al., 2010).
  • Immunization Route: Intranasally
Host Response

Mouse Response

  • Host Strain: C57Bl/6
  • Vaccination Protocol: At the age of 8–9 weeks, mice were randomly distributed into 10 experimental groups of 10 mice each, and the serological status (Neospora-negative) was checked by enzyme-linked immunosorbent assay (ELISA). Mice in groups 1–5 were treated by i.p. injection; mice in group 1 received 100 μl of PBS each (i.p. infection control), group 2 received 100 μl saponin adjuvant (SAP) at 100 μg/ml, group 3 received 10 μg of recNcPDI in SAP, group 4 received 10 μg recNcROP2 in SAP, group 5 received 10 μg recNcMAG1 in SAP. Mice in groups 6–10 were treated by i.n. application through the nares, which was performed under mild isoflurane anaesthesia. Mice in group 6 received 100 μl of PBS/mouse (i.n. infection control), group 7 received 20 μl of cholera toxin adjuvant (CT) at 250 μg/ml, group 8 received 10 μg recNcPDI/mouse in CT, group 9 received 10 μg recROP2 in CT, group 10 received 10 μg recNcMAG1 in CT. These procedures were carried out on days 1, 15 and 30 (Debache et al., 2010).
  • Challenge Protocol: On day 46 all animals were challenged by i.p. inoculation of 1×10^6 freshly purified N. caninum tachyzoites. On day 74, the experiment was terminated and mice were euthanized by CO2 asphyxiation. Those animals exhibiting clinical signs of neosporosis (ruffled coat, apathy, hind limb paralysis) prior to day 74 were euthanized at the onset of these signs (Debache et al., 2010).
  • Efficacy: A 90% protection rate was achieved following intra-nasal vaccination with recNcPDI emulsified in cholera toxin employing the C57Bl/6 mouse cerebral infection model when challenged with Neospora caninum tachyzoites (Debache et al., 2010).
References
Debache et al., 2010: Debache K, Guionaud C, Alaeddine F, Hemphill A. Intraperitoneal and intra-nasal vaccination of mice with three distinct recombinant Neospora caninum antigens results in differential effects with regard to protection against experimental challenge with Neospora caninum tachyzoites. Parasitology. 2010; 137(2); 229-240. [PubMed: 19835644].